Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Scott Kono

Concepts (129)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Carcinoma, Squamous Cell
9
2022
575
0.710
Why?
Carcinoma, Non-Small-Cell Lung
6
2013
953
0.590
Why?
Head and Neck Neoplasms
7
2014
423
0.550
Why?
Lung Neoplasms
7
2022
2148
0.520
Why?
Receptors, Fibroblast Growth Factor
2
2011
62
0.410
Why?
ErbB Receptors
5
2013
553
0.330
Why?
Lymphatic Metastasis
1
2009
275
0.300
Why?
Lymph Node Excision
1
2009
140
0.300
Why?
Empyema, Pleural
1
2007
11
0.280
Why?
Antineoplastic Combined Chemotherapy Protocols
5
2014
1356
0.260
Why?
Drug Resistance, Neoplasm
1
2009
636
0.240
Why?
Antineoplastic Agents
2
2009
1872
0.190
Why?
Quinazolines
2
2013
239
0.190
Why?
Biosimilar Pharmaceuticals
1
2021
25
0.180
Why?
Pyrazoles
2
2013
361
0.170
Why?
Sulfonamides
2
2013
442
0.170
Why?
Delivery of Health Care, Integrated
1
2021
229
0.160
Why?
Receptor Protein-Tyrosine Kinases
2
2011
223
0.160
Why?
Sirolimus
2
2014
181
0.130
Why?
Neoplasm Staging
4
2015
1159
0.130
Why?
Adenocarcinoma
2
2013
787
0.130
Why?
Multi-Institutional Systems
1
2014
7
0.120
Why?
SEER Program
2
2013
193
0.120
Why?
Social Class
1
2015
203
0.110
Why?
Carboplatin
1
2014
134
0.110
Why?
Neoplasm Metastasis
2
2014
519
0.110
Why?
Paranasal Sinus Neoplasms
1
2013
16
0.110
Why?
Chemoprevention
1
2013
86
0.110
Why?
Middle Aged
12
2015
26552
0.100
Why?
Complementary Therapies
1
2013
74
0.100
Why?
Cyclooxygenase Inhibitors
1
2013
72
0.100
Why?
Thyroid Neoplasms
1
2015
271
0.100
Why?
Maintenance Chemotherapy
1
2012
21
0.100
Why?
Carcinoma, Adenoid Cystic
1
2012
16
0.100
Why?
Oropharyngeal Neoplasms
1
2012
39
0.100
Why?
Carcinoma, Large Cell
1
2011
14
0.090
Why?
Autocrine Communication
1
2011
42
0.090
Why?
Gene Rearrangement
1
2011
135
0.090
Why?
Signal Transduction
3
2013
4439
0.090
Why?
Antibodies, Monoclonal, Humanized
1
2014
654
0.090
Why?
Biomedical Research
1
2014
581
0.080
Why?
Papillomavirus Infections
1
2012
258
0.080
Why?
Humans
19
2022
113531
0.080
Why?
Radiotherapy
1
2009
173
0.080
Why?
Genetic Testing
1
2010
381
0.070
Why?
Biomarkers, Tumor
2
2013
1029
0.070
Why?
Thoracic Surgery, Video-Assisted
1
2007
39
0.070
Why?
Pleural Effusion
1
2007
46
0.070
Why?
Combined Modality Therapy
1
2009
1114
0.070
Why?
Protein Kinase Inhibitors
1
2010
779
0.060
Why?
Radiography
1
2007
803
0.060
Why?
Male
11
2015
55112
0.060
Why?
Survival Rate
3
2013
1634
0.060
Why?
Everolimus
2
2014
61
0.050
Why?
Celecoxib
2
2013
38
0.050
Why?
Incidence
3
2015
2310
0.050
Why?
Erlotinib Hydrochloride
2
2013
64
0.050
Why?
Aged
7
2014
18944
0.050
Why?
Female
10
2015
59115
0.050
Why?
United States
4
2022
12137
0.050
Why?
Oxazepines
1
2022
4
0.050
Why?
Aged, 80 and over
4
2013
6296
0.050
Why?
National Cancer Institute (U.S.)
1
2022
40
0.050
Why?
Filgrastim
1
2021
10
0.050
Why?
Class I Phosphatidylinositol 3-Kinases
1
2022
76
0.050
Why?
Infliximab
1
2021
93
0.050
Why?
United States Food and Drug Administration
1
2021
172
0.050
Why?
Imidazoles
1
2022
203
0.040
Why?
Prognosis
3
2013
3318
0.040
Why?
Phosphatidylinositol 3-Kinases
1
2022
324
0.040
Why?
In Situ Hybridization, Fluorescence
2
2011
306
0.040
Why?
Pilot Projects
2
2014
1356
0.040
Why?
Anti-Bacterial Agents
1
2007
1465
0.040
Why?
Treatment Outcome
2
2012
9006
0.040
Why?
Adult
6
2014
30245
0.040
Why?
Michigan
1
2015
96
0.030
Why?
Demography
1
2015
255
0.030
Why?
Health Maintenance Organizations
1
2014
94
0.030
Why?
Maximum Tolerated Dose
1
2014
182
0.030
Why?
Cetuximab
1
2014
89
0.030
Why?
Ethmoid Sinus
1
2013
7
0.030
Why?
Maxillary Sinus Neoplasms
1
2013
7
0.030
Why?
Follow-Up Studies
2
2013
4384
0.030
Why?
Disease-Free Survival
1
2014
617
0.030
Why?
Taxoids
1
2013
93
0.030
Why?
Immunoenzyme Techniques
1
2013
191
0.030
Why?
Survival Analysis
1
2015
1203
0.030
Why?
Drug Administration Schedule
1
2014
712
0.020
Why?
Submandibular Gland Neoplasms
1
2012
1
0.020
Why?
Parotid Neoplasms
1
2012
14
0.020
Why?
Salivary Gland Neoplasms
1
2012
30
0.020
Why?
Recurrence
1
2014
925
0.020
Why?
Mice, Nude
1
2013
625
0.020
Why?
Pemetrexed
1
2011
27
0.020
Why?
Organoplatinum Compounds
1
2011
37
0.020
Why?
Tumor Cells, Cultured
1
2013
834
0.020
Why?
Fibroblast Growth Factor 2
1
2011
81
0.020
Why?
Glutamates
1
2011
55
0.020
Why?
Kaplan-Meier Estimate
1
2013
809
0.020
Why?
Guanine
1
2011
76
0.020
Why?
DNA, Neoplasm
1
2011
154
0.020
Why?
Mutation
2
2011
3313
0.020
Why?
ras Proteins
1
2011
136
0.020
Why?
Blotting, Western
1
2013
1128
0.020
Why?
TOR Serine-Threonine Kinases
1
2013
357
0.020
Why?
Cell Cycle
1
2013
538
0.020
Why?
Proto-Oncogene Proteins p21(ras)
1
2011
227
0.020
Why?
Structure-Activity Relationship
1
2010
497
0.020
Why?
Pharmacogenetics
1
2010
149
0.020
Why?
Multivariate Analysis
1
2013
1421
0.020
Why?
Qualitative Research
1
2013
924
0.020
Why?
Cell Movement
1
2013
852
0.020
Why?
Registries
1
2015
1762
0.020
Why?
Polymerase Chain Reaction
1
2011
984
0.020
Why?
Protein-Tyrosine Kinases
1
2011
390
0.020
Why?
Immunohistochemistry
1
2012
1604
0.020
Why?
Proto-Oncogene Proteins
1
2011
595
0.020
Why?
Retrospective Studies
2
2015
12504
0.020
Why?
Disease Progression
1
2013
2364
0.020
Why?
Cell Proliferation
1
2013
2164
0.020
Why?
Cell Line, Tumor
1
2011
2690
0.010
Why?
Apoptosis
1
2013
2288
0.010
Why?
Risk Factors
1
2015
8606
0.010
Why?
Quality of Life
1
2012
2335
0.010
Why?
Mice
1
2013
14679
0.010
Why?
Young Adult
1
2012
10400
0.010
Why?
Adolescent
1
2012
17724
0.010
Why?
Child
1
2012
18340
0.010
Why?
Animals
1
2013
31162
0.010
Why?
Kono's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)